Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Brequinar||DUP 785|DUP785|DUP-785|NSC368390|NSC-368390|NSC 368390|Bipenquinate||Brequinar (DUP 785) is a small molecule that selectively inhibits the activity of Dihydroorotate dehydrogenase (DHODH), potentially resulting in increased myeloid differentiation and decreased tumor burden (PMID: 27641501, PMID: 32525770).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||acute myeloid leukemia||not applicable||Brequinar||Preclinical - Pdx & cell culture||Actionable||In a preclinical study, Brequinar treatment induced differentiation of acute myeloid leukemia cell lines in culture, reduced colony formation of tumor cells, decreased leukemic burden and leukemia initiating cells, and increased survival in syngeneic mouse models, and led to induced differentiation of tumor cells, inhibition of tumor growth, and increased survival in cell line xenograft models and a patient-derived xenograft (PDX) model (PMID: 27641501).||27641501|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03760666||Phase Ib/II||Brequinar||A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid Leukemia||Recruiting||USA||0|